Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2012. The report specifically addresses a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) related to the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding internal plan transactions rather than a financial performance report.
Material Changes
Following a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK American Depositary Shares), an increase in the notional allocation of ADSs occurred on September 14, 2012, at a price of $45.90 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: September 14, 2012.
- Transaction Price: $45.90 per ADS.
- Involved Parties: Dr. M M Slaoui (Director) and Dr. K Slaoui (Connected Person).
- Allocation Details: Dr. M M Slaoui received 0 ADSs; Dr. K Slaoui received 3 ADSs.
- Context: The transaction resulted from a revaluation of the US Retirement Savings Plan.